Researchers at the Technion-Israel Institute of Technology have suggested a new approach to overcoming anticancer-drug resistance in melanoma based on the discovery of two proteins that together play together a major role in the phenomenon.
The research, published in the Journal of Investigative Dermatology, was headed by Prof. Amir Orian (head of the lab for the study of genetic networks at the Faculty of Medicine and a member of the Technion’s Integrated Cancer Research Center of the Technion’s Rapaport Faculty of Medicine) and Dr. Emily Avitan-Hersh (a lecturer in the Technion’s Faculty of Medicine and deputy director of the dermatology department and a member of the Rambam Clinical Research Institute at Rambam Medical Center), in collaboration with Prof. Ze’ev A. Ronai of the Sanford Burnham Prebys Medical Discovery Institute in California.